ProShare Advisors’s Aquestive Therapeutics AQST Stock Holding History

ProShare Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75.9K	Sell	18,254 -1,985	-10%	-$8.35K	﹤0.01%	1810
2026 Q1	$84K	Sell	20,239 -4,243	-17%	-$17.2K	﹤0.01%	1728
2025 Q4	$158K	Buy	24,482 +5,461	+29%	+$34K	﹤0.01%	1787
2025 Q3	$106K	Sell	19,021 -2,332	-11%	-$10.1K	﹤0.01%	1835
2025 Q2	$70.7K	Buy	21,353 +1,164	+6%	+$3.34K	﹤0.01%	1940
2025 Q1	$58.5K	Sell	20,189 -5,043	-20%	-$15.3K	﹤0.01%	1930
2024 Q4	$89.8K	Buy	25,232 +11,200	+80%	+$51.6K	﹤0.01%	2093
2024 Q3	$69.9K	Buy	+14,032	New	+$54.6K	﹤0.01%	1936

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ProShare Advisors's AQST Position: Q2 2026 in Review

ProShare Advisors reduced its Aquestive Therapeutics (AQST) stake by 9.8% in Q2 2026, selling an estimated $8.35K and leaving 18,254 shares worth $75.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1810.

ProShare Advisors first reported a position in AQST in Q3 2024 and has held it in 8 quarters since. The position peaked at $158K in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

ProShare Advisors held 18,254 shares of Aquestive Therapeutics worth $75.9K as of Q2 2026.
ProShare Advisors sold 1,985 Aquestive Therapeutics shares in Q2 2026, an estimated $8.35K.
Aquestive Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1810 holding.
ProShare Advisors first reported a position in Aquestive Therapeutics in Q3 2024 and has held it in 8 quarters since.
ProShare Advisors's Aquestive Therapeutics position peaked at $158K in Q4 2025.
185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.